- ImmunoGen has reported that preclinical studies with its "humanized"antibody, hN901-DM1, have shown that, at a dose of 300mcg/kg/day for five days, the drug completely eliminated human small-cell lung cancer tumors transplanted into mice, with no tumor recurrence for 200 days. In contrast, treatment with cisplatin and etoposide, as monotherapies and in combination, only briefly delayed tumor growth, even at the maximum tolerated doses. As reported briefly last week (Marketletter April 14), hN901 works by binding specifically with the CD56 marker expressed on all SCLC cells to deliver the maytansinoid drug DM1, which ImmunoGen reports is 100 times more potent than conventional chemotherapeutic agents, directly to the tumor site. The company says that it plans to begin clinical trials with the drug in 1998.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze